Autism spectrum disorder is a heterogeneous neurodevelopmental disease. Currently, no biomarker of this disease is known. Diagnosis is performed through observation, standardized behavioral scales, and interviews with parents. In practice, diagnosis is often delayed to the average age of four years or even more which adversely affects a child's perspective. A laboratory method allowing to detect the disorder at earlier stages is of a great need, as this could help the patients to start with treatment at a younger age, even prior to the clinical diagnosis. Recent evidence indicates that metabolomic markers should be considered as diagnostic markers, also serving for further differentiation and characterization of different subgroups of the autism spectrum. In this study, we developed an ultra-high performance liquid chromatography-tandem triple quadrupole mass spectrometry method for the simultaneous determination of six metabolites in human urine. These metabolites, namely methylguanidine, N-acetyl arginine, inosine, indole-3-acetic acid, indoxyl sulfate and xanthurenic acid were selected as potential biomarkers according to prior metabolomic studies. The analysis was carried out by means of reversed-phase liquid chromatography with gradient elution. Separation of the metabolites was performed on a Phenomenex Luna® Omega Polar C18 (100 × 1.0 mm, 1.6 µm) column at a flow rate of 0.15 mL/min with acetonitrile/water 0.1% formic acid aqueous as the mobile phase. The analysis was performed on a group of children with autism spectrum disorder and age-matched controls. In school children, we have detected disturbances in the levels of oxidative stress markers connected to arginine and purine metabolism, namely methylguanidine and N-acetylargine. Also, products of gut bacteria metabolism, namely indoxyl sulfate and indole-3-acetic acid, were found to be elevated in the patients' group. We can conclude that this newly developed method is fast, sensitive, reliable, and well suited for the quantification of proposed markers.

Department of Pharmaceutical Analysis and Nuclear Pharmacy Faculty of Pharmacy Comenius University in Bratislava Odbojarov 10 832 32 Bratislava Slovakia

Institute of Mathematics and Statistics Faculty of Science Masaryk University Kotlářská 267 2 611 37 Brno Czech Republic

Institute of Neuroimmunology Slovak Academy of Sciences Dubravska cesta 9 84510 Bratislava Slovakia

Institute of Physiology Faculty of Medicine Comenius University in Bratislava Sasinkova 2 813 72 Bratislava Slovakia

Zobrazit více v PubMed

Muhle R.A., Reed H.E., Stratigos K.A., Veenstra-VanderWeele J. The Emerging Clinical Neuroscience of Autism Spectrum Disorder. JAMA Psychiatry. 2018;75:514–523. doi: 10.1001/jamapsychiatry.2017.4685. PubMed DOI

Fakhoury M. Autistic spectrum disorders: A review of clinical features, theories and diagnosis. Int. J. Dev. Neurosci. 2015;43:70–77. doi: 10.1016/j.ijdevneu.2015.04.003. PubMed DOI

Fombonne E. Epidemiological controversies in autism. Swiss. Arch. Neurol. Psychiatry Psychother. 2020;171:3–5. doi: 10.4414/sanp.2020.03084. DOI

Perryman T., Watson L.R., Chumney F. Predictors of the age of autism spectrum disorder diagnosis: A North Carolina Cohort. Autism Dev. Lang. Impair. 2018;3:1–10. doi: 10.1177/2396941517751892. DOI

Shen L.-M., Liu X., Zhang H., Lin J., Feng C., Iqbal J. Biomarkers in autism spectrum disorders: Current progress. Clin. Chim. Acta. 2020;502:41–54. doi: 10.1016/j.cca.2019.12.009. PubMed DOI

Want E.J., Wilson I.D., Gika H.G., Theodoridis G., Plumb R.S., Shockcor J.P., Holmes E., Nicholson J.K. Global metabolic profiling procedures for urine using UPLC–MS. Nat. Protoc. 2010;5:1005–1018. doi: 10.1038/nprot.2010.50. PubMed DOI

Ruggeri B., Sarkans U., Schumann G., Persico A.M. Biomarkers in autism spectrum disorder: The old and the new. Psychopharmacology. 2014;231:1201–1216. doi: 10.1007/s00213-013-3290-7. PubMed DOI

Yan M., Xu G. Current and future perspectives of functional metabolomics in disease studies–A review. Anal. Chim. Acta. 2018;1037:41–54. doi: 10.1016/j.aca.2018.04.006. PubMed DOI

Diémé B., Mavel S., Blasco H., Tripi G., Bonnet-Brilhault F., Malvy J., Bocca C., Andres C.R., Nadal-Desbarats L., Emond P. Metabolomics Study of Urine in Autism Spectrum Disorders Using a Multiplatform Analytical Methodology. J. Proteome Res. 2015;14:5273–5282. doi: 10.1021/acs.jproteome.5b00699. PubMed DOI

Frye R.E., Slattery J. The potential role of nitrous oxide in the etiology of autism spectrum disorder. Transl. Psychiatry. 2016;6:e812. doi: 10.1038/tp.2016.89. PubMed DOI PMC

Yap I.K.S., Angley M., Veselkov K.A., Holmes E., Lindon J.C., Nicholson J.K. Urinary Metabolic Phenotyping Differentiates Children with Autism from Their Unaffected Siblings and Age-Matched Controls. J. Proteome Res. 2010;9:2996–3004. doi: 10.1021/pr901188e. PubMed DOI

Ming X., Stein T.P., Barnes V., Rhodes N., Guo L. Metabolic Perturbance in Autism Spectrum Disorders: A Metabolomics Study. J. Proteome Res. 2012;11:5856–5862. doi: 10.1021/pr300910n. PubMed DOI

Emond P., Mavel S., Aïdoud N., Nadal-Desbarats L., Montigny F., Bonnet-Brilhault F., Barthélémy C., Merten M., Sarda P., Laumonnier F., et al. GC-MS-based urine metabolic profiling of autism spectrum disorders. Anal. Bioanal. Chem. 2013;405:5291–5300. doi: 10.1007/s00216-013-6934-x. PubMed DOI

Gevi F., Zolla L., Gabriele S., Persico A.M. Urinary metabolomics of young Italian autistic children supports abnormal tryptophan and purine metabolism. Mol. Autism. 2016;7:1–11. doi: 10.1186/s13229-016-0109-5. PubMed DOI PMC

Bitar T., Mavel S., Emond P., Nadal-Desbarats L., Lefèvre A., Mattar H., Soufia M., Blasco H., Vourc’H P., Hleihel W., et al. Identification of metabolic pathway disturbances using multimodal metabolomics in autistic disorders in a Middle Eastern population. J. Pharm. Biomed. Anal. 2018;152:57–65. doi: 10.1016/j.jpba.2018.01.007. PubMed DOI

Xiong X., Liu D., He W., Sheng X., Zhou W., Xie N., Liang H., Zeng T., Li T., Wang Y. Identification of gender-related metabolic disturbances in autism spectrum disorders using urinary metabolomics. Int. J. Biochem. Cell Biol. 2019;115:105594. doi: 10.1016/j.biocel.2019.105594. PubMed DOI

Tachikawa M., Hosoya K.-I. Transport characteristics of guanidino compounds at the blood-brain barrier and blood-cerebrospinal fluid barrier: Relevance to neural disorders. Fluids Barriers CNS. 2011;8:13. doi: 10.1186/2045-8118-8-13. PubMed DOI PMC

Yao J.K., Dougherty G.G., Jr., Reddy R.D., Keshavan M.S., Montrose D.M., Matson W.R., McEvoy J., Kaddurah-Daouk R. Homeostatic Imbalance of Purine Catabolism in First-Episode Neuroleptic-Naïve Patients with Schizophrenia. PLoS ONE. 2010;5:e9508. doi: 10.1371/journal.pone.0009508. PubMed DOI PMC

Damodaran L.P.M., Arumugam G. Urinary oxidative stress markers in children with autism. Redox Rep. 2011;16:216–222. doi: 10.1179/1351000211Y.0000000012. PubMed DOI PMC

Bent S., Lawton B., Warren T., Widjaja F., Dang K., Fahey J.W., Cornblatt B., Kinchen J.M., Delucchi K., Hendren R.L. Identification of urinary metabolites that correlate with clinical improvements in children with autism treated with sulforaphane from broccoli. Mol. Autism. 2018;9:35. doi: 10.1186/s13229-018-0218-4. PubMed DOI PMC

Anderson G.M. Autism Biomarkers: Challenges, Pitfalls and Possibilities. J. Autism Dev. Disord. 2015;45:1103–1113. doi: 10.1007/s10803-014-2225-4. PubMed DOI

Ghanizadeh A., Akhondzadeh S., Hormozi M., Makarem A., Abotorabi-Zarchi M., Firoozabadi A. Glutathione-Related Factors and Oxidative Stress in Autism, A Review. Curr. Med. Chem. 2012;19:4000–4005. doi: 10.2174/092986712802002572. PubMed DOI

Chauhan A., Chauhan V. Oxidative stress in autism. Pathophysiology. 2006;13:171–181. doi: 10.1016/j.pathophys.2006.05.007. PubMed DOI

Bjørklund G., Meguid N.A., El-Bana M.A., Tinkov A.A., Saad K., Dadar M., Hemimi M., Skalny A.V., Hosnedlová B., Kizek R., et al. Oxidative Stress in Autism Spectrum Disorder. Mol. Neurobiol. 2020;57:2314–2332. doi: 10.1007/s12035-019-01742-2. PubMed DOI

McElhanon B.O., McCracken C., Karpen S., Sharp W.G. Gastrointestinal Symptoms in Autism Spectrum Disorder: A Meta-analysis. Pediatrics. 2014;133:872–883. doi: 10.1542/peds.2013-3995. PubMed DOI

Felice V.D., O’Mahony S.M. The microbiome and disorders of the central nervous system. Pharmacol. Biochem. Behav. 2017;160:1–13. doi: 10.1016/j.pbb.2017.06.016. PubMed DOI

Li Q., Zhou J.-M. The microbiota–gut–brain axis and its potential therapeutic role in autism spectrum disorder. Neurosciences. 2016;324:131–139. doi: 10.1016/j.neuroscience.2016.03.013. PubMed DOI

Strati F., Cavalieri D., Albanese D., De Felice C., Donati C., Hayek J., Jousson O., Leoncini S., Renzi D., Calabrò A., et al. New evidences on the altered gut microbiota in autism spectrum disorders. Microbiome. 2017;5:1–11. doi: 10.1186/s40168-017-0242-1. PubMed DOI PMC

Watanabe K., Watanabe T., Nakayama M. Cerebro-renal interactions: Impact of uremic toxins on cognitive function. NeuroToxicology. 2014;44:184–193. doi: 10.1016/j.neuro.2014.06.014. PubMed DOI

Lord C., Risi S., Lambrecht L., Cook E.H., Jr., Leventhal B., DiLavore P.C., Pickles A., Rutter M. The Autism Diagnostic Observation Schedule—Generic: A Standard Measure of Social and Communication Deficits Associated with the Spectrum of Autism. J. Autism Dev. Disord. 2000;30:205–223. doi: 10.1023/A:1005592401947. PubMed DOI

Lord C., Rutter M., Le Couteur A. Autism Diagnostic Interview-Revised: A revised version of a diagnostic interview for caregivers of individuals with possible pervasive developmental disorders. J. Autism Dev. Disord. 1994;24:659–685. doi: 10.1007/BF02172145. PubMed DOI

R Core Team . A Language and Environment for Statistical Computing. R Foundation for Statistical Computing; Vienna, Austria: 2020.

Wilcox R. Introduction to Robust Estimation and Hypothesis Testin. 3rd ed. Academic Press; Cambridge, MA, USA: 2011.

Welch B.L. The generalization of ‘student’s’ problem when several different population varlances are involved. Biometrics. 1947;34:28–35. doi: 10.1093/biomet/34.1-2.28. PubMed DOI